Antiepilepsy Drugs Market Information, Types of seizures (Generalized seizures and Partial-onset seizures), By Generation (First, second and third) - Forecast to 2030

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s five forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global anti-epilepsy drugs market, by Types Of Seizures

5.1 Introduction

5.1.1 Generalized seizures

5.1.2 Partial-onset seizures

5.1.3 Others

6 Global anti-epilepsy drugs market, by Generation

6.1 Introduction

6.1.1 First generation

6.1.2 Second generation

6.1.3 Third generation

7 Global anti-epilepsy drugs market, by Regions

7.1 Introduction

7.1.1 Americas

7.1.1.1 North America

7.1.1.2 South America

7.1.2 Europe

7.1.2.1 Germany

7.1.2.2 France

7.1.2.3 UK

7.1.2.4 Italy

7.1.2.5 Spain

7.1.2.6 Rest of Europe

7.1.3 Asia Pacific

7.1.3.1 Japan

7.1.3.2 China

7.1.3.3 India

7.1.3.4 Republic of Korea

7.1.3.5 Rest of Asia Pacific

7.1.4 Middle East & Africa

8 Company Landscape

8.1 Introduction

8.1.1 Mergers Acquisitions

8.1.2 Collaborations

8.1.3 Release/New Product Launches

8.1.4 Other (Expansion, Updates, Partnership)

9 Company Profile

9.1 Pfizer, Inc.

9.1.1 Company Overview

9.1.2 Product/Business Segment Overview

9.1.3 Financials

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Johnson & Johnson

9.2.1 Overview

9.2.2 Product/Business Segment Overview

9.2.3 Financials

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 UCB Pharma Ltd.

9.3.1 Overview

9.3.2 Product/Business Segment Overview

9.3.3 Financials

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.4 Abbott Laboratories

9.4.1 Overview

9.4.2 Product/Business Segment Overview

9.4.3 Financials

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.5 GlaxoSmithKline plc

9.5.1 Overview

9.5.2 Product/Business Segment Overview

9.5.3 Financials

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.6 Novartis International AG

9.6.1 Overview

9.6.2 Product/Business Segment Overview

9.6.3 Financials

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.7 Sanofi S.A.

9.7.1 Overview

9.7.2 Product/Business Segment Overview

9.7.3 Financials

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.8 Shire Pharmaceuticals Limited

9.8.1 Overview

9.8.2 Product/Business Segment Overview

9.8.3 Financials

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.9 Cephalon Inc

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

10 Others

11 Appendix

List of Tables

TABLE 1 GLOBAL ANTI-EPILEPSY DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES

FIGURE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION

FIGURE 5 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY REGION

FIGURE 6 GLOBAL ANTI-EPILEPSY DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)